Across TCGA pan-cancer cohorts, IMMP2L mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IMMP2L data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IMMP2L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IMMP2L expression acts as an unfavorable survival marker.

PDAC and CCRCC are the cancer types where IMMP2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.292	0.860	.024	6	view →
CCRCC	DFS	Median	IV	0.128	0.794	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IMMP2L tumor-vs-normal RNA expression · all IMMP2L data types